Spontaneous portosystemic shunts on CT scans in patients with cirrhosis were associated with higher mortality and risk of complications, including portal vein thrombosis, hepatic encephalopathy, an... Background Cirrhosis leads to portal hypertension and to the consequent formation of spontaneous portosystemic shunts (SPSSs), leading to complications related to the diversion of portal blood into...
Beta-thalassemia represents a heterogeneous group of haemoglobin inherited disorders, among the most common genetic diseases in the world, frequent in the Mediterranean basin. As beta-thalassemia patients’ survival has increased over time, previously unknown complications are observed with increasing frequency. Among them, an increased risk of hepatocellular carcinoma (HCC) has been registered. Our aim is to reduce inequalities in diagnosis and treatment and to offer patients univocal recommendations in any institution.The members of the panel - gastroenterologists, radiologists, surgeons and oncologists -were selected on the basis of their publication records and expertise. Thirteen clinical questions, derived from clinical needs, and an integration of all the committee members’ suggestions, were formulated. Modified Delphi approach involving a detailed literature review and the collective judgement of experts, was applied to this work.Thirteen statements were derived from expert opinions’ based on the current literature, on recently developed reviews and on technological advancements. Each statement is discussed in a short paragraph reporting the current key evidence. As this is an emerging issue, the number of papers on HCC in beta-thalassemia patients is limited and based on anecdotal cases rather than on randomized controlled studies. Therefore, the panel has discussed, step by step, the possible differences between beta-thalassemia and non beta-thalassemia patients. Despite the paucity of the literature, practical and concise statements were generated.This paper offers a practical guide organized by statements describing how to manage HCC in patients with beta-thalassemia.
Mechanical thrombectomy is a standard treatment for acute stroke, but it can be technically challenging in elderly patients with difficult vascular anatomy. To overcome this issue, we propose a new endovascular approach called the “tightrope” technique. This technique uses a stiff guidewire and a standard angiographic catheter to straighten the internal carotid artery (ICA) tortuosity, allowing the guiding catheter to be positioned next to the intracranial level. We retrospectively evaluated all the procedures in which the “tightrope” technique was used. This approach involves advancing a 0.035″ Advantage stiff guidewire and a standard 4 Fr angiographic catheter through the vascular tortuosity. The catheter is twisted over the guide wire in a clockwise direction, gaining tension that gradually straightens the vascular axis, allowing the guiding catheter to pass up to the distal ICA. Between June 2022 and March 2023, we successfully performed consecutive mechanical thrombectomy procedures using the tightrope technique in 11 patients with highly tortuous ICA segments. In all cases, we were able to safely advance the catheter system up to the distal cervical ICA. Although our study included a small cohort of patients, the “tightrope” technique proved to be successful in all patients, allowing for safe advancement of the guiding catheter toward extremely tortuous anatomy. However, further validation in a larger patient population is necessary to determine the technique's effectiveness and safety profile.
E11577 Background: To evaluate the effectiveness, the toxicity and survival rates of radioembolization with yttrium-90 (Y90), in patients affected by advanced breast liver metastasis refractory to chemotherapy through our 5-year experience Methods: From February 2005 to January 2010, we treated 45 patients affected by breast cancer. All patients were preliminary evaluated by CT, PET. 32 patients underwent preliminary hepatic angiography with infusion of technetium macroaggregated (Tc-99 m) albumin (MAA) to evaluate hepatic vasculature and hepato-pulmonary shunts. Patients with a bilirubin level >1.8 mg/dl and pulmonary shunt >20% were excluded. All patient were treated, under fluoroscopic guidance, by implantation of Y90 microspheres; the correct dose was calculated on the basis of liver tumor involvement and the body surface area formula. All patients were discharged the day after treatment. Follow-up was scheduled in 8- and 12-week CT and PET controls Results: We observed, according to RECIST criteria, complete response/partial response (CR/PR) in 24 patients, stable disease (SD) in 17 patients, and progressive disease (PD) in 8 patients. Technical success rate andl effectiveness, estimated at 3 months were respectively of (98%?) and (80%). Side effects graded by Common Terminology Criteria on Adverse Events were represented by one grade 4 hepatic failure, one grade 2 gastritis, and one grade 2 cholecystitis. The median survival and the progression-free survival calculated were 354 and 279 days, respectively. Conclusions: Liver 90Y radioembolization is effective and well tolerated in patients with liver metastases from breast cancer. Response to therapy was supported by the decrease in tumor size and activity. Further investigation is warranted to prove survival benefit.
This article aims to retrospectively assess the safety, efficacy and feasibility of using intravenous cangrelor in the acute treatment of small ruptured cerebral aneurysms (less than 6 mm) with FD, discussing its potential advantages over traditional antiplatelet agents and its implication on clinical practice. This is a single-center retrospective study conducted on patients who underwent emergency FD implantation for hemorrhagic stroke due to acute rupture of intracranial aneurysms between January 2020 and February 2024. Patients were medicated with cangrelor in association with acetylsalicylic acid (ASA) before stent deployment. All patients were treated within 5 h from hospital arrival and received intravenous cangrelor (30 µg/kg administered over less than 1 min) + ASA (300 mg), followed by an infusion of cangrelor at 4 µg/kg/minute for either 12 or 24 h, as per clinical scenario. Procedural complications related to antiplatelet therapy itself, rate of complete aneurysm occlusion at 12-months follow-up and clinical outcome in terms of functional scale (mRS) were evaluated. Ten patients were retrospectively evaluated. The interventions showed a favorable outcome with no reported thromboembolic or hemorrhagic complications within the first 24 h post-procedure. Six out of ten patients (60%) of patients had a good clinical prognosis (mRS 0–2), and MRA/CTA follow-ups indicated a complete resolution of aneurysms in the majority of cases (five out of seven patients (71.5%) occlusion rate at 12 months). In our limited experience, cangrelor has proven to be safe and effective in preventing thromboembolic complications after acute FD implantation for ruptured intracranial aneurysms; further studies with larger populations and comparative methodologies are required to incorporate cangrelor into standard neurovascular practice.